Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00661674 · ClinicalTrials.gov registry record · NA
Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT00661674: Completed NA study, sponsored by Stanford University.
NCT00661674 is a NA study that has completed, run by Stanford University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00661674, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects--such as agitation and nausea--if opioid medications are suddenly stopped. We are interested in knowing if a medication named Ondansetron can help ease or prevent symptoms associated with opioid withdrawal. We are also interested in knowing if a similar (but more potent FDA-approved drug, palonosetron) can more effectively treat withdrawal symptoms with or without combination with an antihistamine called hydroxyzine (vistaril).
Interventions
- OTHER Placebo
- DRUG Palonosetron
- DRUG Hydroxyzine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-04 |
| Est. Completion | 2008-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00661674
The ClinicalTrials.gov registry entry for NCT00661674 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00661674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00661674 about?
NCT00661674 is a clinical study titled "Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal". Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects--such as agitation and nausea--if opioid medications are suddenly stopped. We are interested in knowing if a medication named Ondansetron can help ease o...
What is the current status of trial NCT00661674?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2008-04. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00661674?
The interventions under investigation include: Placebo (OTHER), Palonosetron (DRUG), Hydroxyzine (DRUG).
Who is sponsoring clinical trial NCT00661674?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.